In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VenatoRx Pharmaceuticals Inc.

www.venatorx.com

Latest From VenatoRx Pharmaceuticals Inc.

Finance Watch: Cell And Gene Therapy Fundraising Down Overall In Q2, But VC Deals Still Soared

Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.

Financing Regenerative Medicine

Antibiotic Stakeholders Discuss Ethics Of Testing Limited Population Drugs In Broader Populations

The US FDA's LPAD draft guidance suggests that clinical trials for potential limited population antibacterials would enroll broader patient populations. But is that an ethical approach?

Clinical Trials Infectious Diseases

Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris

Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.

Deals Business Strategies

Venture Funding Deals: Complexa Raises $62m; Evelo, Kezar Bring In $50m Each

Complexa topped the list of recent venture capital financings with a $62m Series C round, followed by Evelo and Kezar with $50m Series B rounds and LogicBio with a $45m Series B.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • VenatoRx Pharmaceuticals Inc.
  • Senior Management
  • Christopher J Burns, PhD, Pres. & CEO
    Tim Henkel, MD, PhD, CMO
    Tony Meehan, PhD, SVP, Bus. & Corp. Dev.
    Lisa Wittmer, PhD, Chief Dev. Officer
  • Contact Info
  • VenatoRx Pharmaceuticals Inc.
    Phone: (610) 644-8935
    30 Spring Mill Dr.
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register